ECDB-Endometrial cancer gene database

REFERENCES

Gene Name	Gene ID	Pubmed ID	Classification	Mechanism	Marker	Type	Normal Cases	Disease Cases	Age	Mean Age	Place	FIGO	Grade	Remark	Title	Journal	Volume	Year
CYP1B1	1545	12873984	-	Polymorphism	-	-	202	113 [86 endometrioid cancer; 6 adenocarcinoma; 2 adenosquamous; 2 clear cell cancer; 17 unkown type]	29 to 87	61.7	Department of Gynecology; Hospital of Hokkaido University; Japan	-	-	[1] The rare polymorphisms at codons 119 and 432 of CYP1B1 gene have higher risk for endometrial cancer; and positive correlations with ERalpha and ERbeta expressions in endometrial cancer. [2] The distributions of CYP1B1 genotypes at codons 119 and 432 were significantly different between endometrial cancer patients and healthy normal controls. The relative risks of 119T/T and 432G/G in endometrial cancer were calculated as 3.32 and 2.49 compared with wild-types. The 119T/T showed significant correlation for positivities of ERalpha and ERbeta.	CYP1B1 gene polymorphisms have higher risk for endometrial cancer; and positive correlations with estrogen receptor alpha and estrogen receptor beta expressions	Cancer Research	63(14):3913-8	2003
CYP1B1	1545	14656940	-	-	-	-	666	222	-	59	-	-	-	[1] CYP1B1 Ser allele may decrease endometrial cancer risk by altering the production of catechol estrogens. However; further studies are warranted to elucidate the role of CYP1B1 in endometrial cancer. [2] Carriers of the CYP1B1 Ser allele had a statistically significant decreased risk of endometrial cancer (OR = 0.62; 95% CI; 0.42-0.91); there was no significant association between the CYP1B1 Val allele and endometrial cancer risk (OR = 1.10; 95% CI; 0.75-1.59). [3] The CYP1B1 Ser allele is associated with a decreased endometrial cancer risk may be due to alterations in the production of reactive catechol estrogens.	Cytochrome P450 1B1 and catechol-O-methyltransferase polymorphisms and endometrial cancer susceptibility.	Carcinogenesis	25(4):559-65	2004
CYP1B1	1545	19690133	-	Up regulation/ Over expression/High expression	Biomarker	-	12	36	-	-	-	-	-	[1] CYP1B1 up-regulation plays a crucial role in endometrial carcinogenesis by targeting multiple pathways. CYP1B1 inhibition in endometrial carcinomas could be a useful therapeutic approach as it regulates several potential anticancer targets like cyclin E1; Skp2; and TRAIL. [2] CYP1B1 depletion decreased the invasive potential of the endometrial cancer cells and expression of melanoma cell adhesion molecule (MCAM). [3] CYP1B1 depletion in endometrial carcinoma cells leads to decreased cellular proliferation and induces G(0)-G(1) cell cycle arrest. Significantly; CYP1B1 knockdown leads to down-regulated expression of cyclin E1; S-phase kinase-associated protein 2 (SKP2); minichromosome maintenance complex component 4 (MCM4); and RAD51 and up-regulation of p27(Kip1).	Functional significance of cytochrome P450 1B1 in endometrial carcinogenesis.	Cancer Research	69(17):7038-45	2009